PAI
XENE icon

Palo Alto Investors’s Xenon Pharmaceuticals XENE Stock Holding History

Palo Alto Investors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.99M Sell
51,345
-45,174
-47% -$2.08M 0.46% 30
2025
Q4 		$4.33M Buy
+96,519
New +$4.05M 0.6% 31

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Palo Alto Investors's XENE Position: Q1 2026 in Review

Palo Alto Investors reduced its Xenon Pharmaceuticals (XENE) stake by 47% in Q1 2026, selling an estimated $2.08M and leaving 51,345 shares worth $2.99M. The position accounts for 0.46% of the portfolio, ranked #30.

Palo Alto Investors first reported a position in XENE in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.33M in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Palo Alto Investors held 51,345 shares of Xenon Pharmaceuticals worth $2.99M as of Q1 2026.
  • Palo Alto Investors sold 45,174 Xenon Pharmaceuticals shares in Q1 2026, an estimated $2.08M.
  • Xenon Pharmaceuticals made up 0.46% of Palo Alto Investors's portfolio in Q1 2026, its #30 holding.
  • Palo Alto Investors first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Palo Alto Investors's Xenon Pharmaceuticals position peaked at $4.33M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.